NEWBORN SCREENING FOR DUCHENNE MUSCULAR DYSTROPHY

That this House welcomes the report of the All Party Parliamentary Group on Muscular Dystrophy on newborn screening for Duchenne muscular dystrophy; acknowledges the support provided by the Muscular Dystrophy Campaign in drawing attention to these important issues; notes that with potential treatments for the condition in or entering clinical trial, planning must begin now for a newborn screening programme; further notes the significant advances in genetic medicine that have taken place in recent years; and calls on the National Screening Committee to reflect these advances by updating its appraisal criteria for newborn screening programmes.